Intradermal vaccination to protect against yellow fever and influenza

Current Topics in Microbiology and Immunology

Volumn 351, Issue 1, 2012, Pages 159-179

  Roukens, A H E ^a   Gelinck, L B S ^b   Visser, L G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS LIKE PARTICLE VACCINE; YELLOW FEVER VACCINE;

ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COST CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INNATE IMMUNITY; INTRACUTANEOUS VACCINATION; MEDICAL HISTORY; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE DRUG DOSE; VIRUS STRAIN; YELLOW FEVER;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DERMIS; FLAVIVIRUS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; LANGERHANS CELLS; MICE; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES; YELLOW FEVER;

EID: 80053557195     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_124     Document Type: Article

References (86)

1. Akondy RS, Monson ND, Miller JD et al (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 183:7919-7930
2. Allan RS, Waithman J, Bedoui S et al (2006) Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25:153-162 (Pubitemid 44066832)
3. Appleby JC, Himmelweit F, Stuart-Harris CH (1951) Immunisation with influenza virus A vaccines, comparison of intradermal and subcutaneous routes. Lancet 1:1384-1387
4. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P (2009) Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 27:7304-7312
5. Bains I, Antia R, Callard R, Yates AJ (2009) Quantifying the development of the peripheral naive CD4+ T-cell pool in humans. Blood 113:5480-5487
6. Barwick R (2004) History of thymoma and yellow fever vaccination. Lancet 364:936 (Pubitemid 39208454)
7. Belshe RB, Newman FK, Cannon J et al (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351:2286-2294 (Pubitemid 39552744)
8. Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD (1998) The plea against annual influenza vaccination 'The Hoskins' Paradox' revisited. Vaccine 16:1929-1932 (Pubitemid 28473937)
9. Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD (2004) Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103:125-132 (Pubitemid 38649071)
10. Centers for Disease Control and Prevention (CDC) 2009, Pandemic influenza A (H1N1) virus infections-Chicago, Illinois, April-July 2009. MMWR Morb Mortal Wkly Rep 58(33) 913-918.
11. Chlíbek R, Smetana J, Sindelár R, Cecetková B, Prymula R, Kohl I (2007) Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age-impact of risk factors. Epidemiol Mikrobiol Imunol 56:119-128 (Pubitemid 47337839)
12. Cohen Stuart J, Hamann D, Borleffs J, Roos M, Miedema F, Boucher C, de Boer R (2002) Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age. AIDS 16:2263-2266 (Pubitemid 35449011)
13. Cubas R, Zhang S, Kwon S et al (2009) Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 32: 118-128
14. De Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol 115:63-73
15. De Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, van der Ende ME (2008) A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 197:292-294 (Pubitemid 351263450)
16. Douek DC, McFarland RD, Keiser PH et al (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396:690-695 (Pubitemid 29003949)
17. Fox JP, Luty Kossobudski S, Fonseca da Cunha J (1943) Field studies on the immune response to 17D yellow fever virus. Relation to virus substrain, dose and route of inoculation. Am J Hyg 38:113-138
18. Gaspar LP, Mendes YS, Yamamura AM et al (2008) Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 150:57-62
19. Gaucher D, Therrien R, Kettaf N et al (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205:3119-3131
20. Gelinck LBS, Teng YKO, Rimmelzwaan GF, Van den Bemt BJF, Kroon FP, Van Laar JM (2007) Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66:1402-1403 (Pubitemid 47492493)
21. Gelinck LB, van den Bemt BJ, Marijt WA, van der Bijl AE, Visser LG, Cats HA, Rimmelzwaan GF, Kroon FP (2009) Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 27:2469-2474
22. Glenn GM, Kenney RT (2006) Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 304:247-268 (Pubitemid 47413300)
23. Gould EA, Buckley A, Barrett ADT, Cammack N (1986) Neutralizing (54 K) and nonneutral-izing (54 K and 48 K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 67:591-595 (Pubitemid 16158597)
24. Greenberg ME, Lai MH, Hartel GF et al (2009) Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361:2405-2413
25. He Y, Zhang J, Donahue C, Falo LD Jr (2006) Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24:643-656
26. Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, Norris SL, Anderson EL (2006) Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 24:2843-2849
27. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M (2008) Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 198:650-658
28. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A (1979) Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1:33-35 (Pubitemid 9084475)
29. Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY et al (2003) Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19:47-57 (Pubitemid 36859900)
30. Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, Kim SR, Kim WJ, Cheong HJ (2009) Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 81:722-727
31. Kelly H, Grant K (2009) Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14. pii: 19288
32. Kengsakul K, Sathirapongsasuti K, Punyagupta S (2002) Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85:131-134
33. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351:2295-2301 (Pubitemid 39552745)
34. Khanlou H, Sanchez S, Babaie M, Chien C, Hamwi G, Ricaurte JC et al (2006) The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients. Arch Intern Med 166:1417 (Pubitemid 44036355)
35. Kunisaki KM, Janoff EN (2009) Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9:493-504
36. Lambert PH, Laurent PR (2008) Intradermal vaccine delivery: Will new delivery systems transform vaccine administration? Vaccine 26:3197-3208
37. Le Borgne M, Etchart N, Goubier A et al (2006) Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 24:191-201 (Pubitemid 43214588)
38. Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275-306
39. Lynch HE, Goldberg GL, Chidgey A, Van den Brink MR, Boyd R, Sempowski GD (2009) Thymic involution and immune reconstitution. Trends Immunol 30:366-373
40. Mackenzie JS, Fimmel PJ (1978) The effect of ABO blood groups on the incidence of epidemic influenza and on the response to live attenuated and detergent split influenza virus vaccines. J Hyg (Lond) 80:21-30 (Pubitemid 8258298)
41. Macroepidemiology of Influenza Vaccination (MIV) Study Group (2005) The macro-epidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 23:5133-5143
42. Madhi S et al. (2009) Efficacy of influenza vaccine in HIV-infected (HIV+) adults: a double-blind, placebo randomised controlled trial in South Africa. In: 5th IAS conference on HIV pathogenesis, treatment and prevention. 19-22 July 2009, Cape Town. Late breaker poster LBPEB04. http://www.ias2009.org/ pag/Abstracts.aspx?AID=3805
43. Manuel O, Humar A, Chen MH et al (2007) Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 11:2567-2572 (Pubitemid 47561624)
44. Mar ID, Niang I, Guicheney A, Berne C, Collomb H, Rey M, Satgé P (1967) Encephalitis following anti-yellow fever vaccination (from 248 cases observed at Dakar in 1965). Ann Pediatr (Paris) 143:181-191
45. Marianneau P, George-Courbot M, Deubel V (2001) Rarity of adverse effects after 17D yellow-fever vaccination. Lancet 358:84-85 (Pubitemid 32709840)
46. Mason RA, Tauraso NM, Spertzel RO, Ginn RK (1973) Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25:539-544
47. Mateo RI, Xiao SY, Travassos da Rosa AP, Lei H, Guzman H, Lu L, Tesh RB (2007) Yellow fever 17-D vaccine is neurotropic and produces encephalitis in immunosuppressed hamster. Am J Trop Med Hyg 77:919-924 (Pubitemid 351837842)
48. McCarroll JR, Kilbourne ED (1958) Immunization with Asian-strain influenza vaccine, equivalence of the subcutaneous and intradermal routes. NEJM 259:618-621
49. McLachlan JB, Shelburne CP, Hart JP et al (2008) Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 14:536-541 (Pubitemid 351655217)
50. McMichael AJ, Gotch F, Cullen P, Askonas B, Webster RG (1981) The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 43:276-284 (Pubitemid 11138262)
51. Monath TP (2005) Yellow fever vaccine. Expert Rev Vaccines 4:553-574 (Pubitemid 41297302)
52. Monath TP (2008a) Yellow fever. In: Plotkin SA, Orenstein WA, Paul A (eds) Vaccines, 5th ed. Saunders Elsevier, Philadelphia, p 959.
53. Monath TP (2008b) Treatment of yellow fever. Antiviral Res 78:116-124 (Pubitemid 351381173)
54. Monath TP, Cetron MS, McCarthy K et al (2005) Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 1:207-214
55. Nicolas JF, Guy B (2008) Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 7:1201-1214
56. Niedrig M, Lademann M, Emmerich P, Lafrenz M (1999) Assessment of IgG antibodies against yellow fever firus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 12:867-871 (Pubitemid 30041042)
57. Oren S, Mandelboim M, Braun-Moscovici et al (2008) Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 67:937-941 (Pubitemid 351956654)
58. World Health Organisation (2003) Yellow fever vaccine. WHO position paper, Wkly Epidemiol Rec 40:349-359
59. Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG (2007) Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 14:189-193
60. Palmer DR, Fernandez S, Bisbing J et al (2007) Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 88:148-156 (Pubitemid 46085125)
61. Pape KA, Catron DM, Itano AA, Jenkins MK (2007) The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 26:491-502 (Pubitemid 46602995)
62. Pfister G, Savino W (2008) Can the immune system still be efficient in the elderly? An immunological and immunoendocrine therapeutic perspective. Neuroimmunomodulation 15:351-364
63. Pincus S, Mason PW, Konishi E, Fonseca BA, Shope RE, Rice CM, Paoletti E (1992) Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever virus encephalitis. Virology 187:290-297
64. Plotkin SA (2008) Correlates of vaccine-induced immunity. Clin Infect Dis 47:401-409 (Pubitemid 352009364)
65. Pulendran B, Ahmed R (2006) Translating innate immunity into immunological memory: implications for vaccine development. Cell 124:849-863 (Pubitemid 43261457)
66. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203:413-424 (Pubitemid 43290850)
67. Roukens AH, Visser LG (2008) Yellow fever vaccine: past, present and future. Expert Opin Biol Ther 8:1787-1795
68. Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG (2008) Intradermally administered Yellow Fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS ONE 3:e1993
69. Roukens AH, Vossen AC, van Dissel JT, Visser LG (2009) Reduced intradermal test dose of yellow fever induces protective immunity in individuals with egg allergy. Vaccine 27:2408-2409
70. Russell CA, Jones TC, Barr IG et al (2008) The global circulation of seasonal influenza A (H3N2) viruses. Science 320:340-346 (Pubitemid 351555652)
71. Ryan J, Zoellner Y, Gradl B, Palache B, Medema J (2006) Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24:6812-6822 (Pubitemid 46137928)
72. Sellards AW (1931) The behaviour of the virus of yellow fever in monkeys and mice. Proc Natl Acad Sci USA 17:339-343
73. Siegrist CA (2008) Vaccine immunology. In: Plotkin S, Orenstein W, Offit P (eds) Vaccines, 5th edn. Saunders Elsevier, Philadelphia
74. Skobe M, Detmar M (2000) Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc 5:14-19 (Pubitemid 32044084)
75. Smedley J, Poole J, Waclawski E et al (2007) Influenza immunisation: attitudes and beliefs of UK healthcare workers. Occup Environ Med 64:223-227 (Pubitemid 46663057)
76. Smith W, Andrews C, Laidlaw P (1933) A virus obtained from influenza patients. Lancet 2:66-68
77. Smith DJ, Forrest S, Ackley DH, Perelson AS (1999) Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA 96:14001-14006
78. Stokes A, Bauer JH, Hudson NP (2001) The transmission of yellow fever to Macacus rhesus. Rev Med Virol 11:141-148 (Pubitemid 32510198)
79. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K (2009) Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematol 49:9-13
80. Tasker SA, Treanor JJ, Paxton WB, Wallace MR (1999) Efficacy of influenza vaccination in HIV-infected persons: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 131:430-433 (Pubitemid 29444433)
81. Theiler M, Smith HH (1937) The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65:787-800
82. Treanor JJ (2009) Influenza viruses, including avian influenza and swine influenza. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th edn. Elsevier, Philadelphia
83. Van Assen S, Holvast A, Benne CA et al (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62:75-81
84. Van Der Kolk LE, Baars JW, Prins MH, van Oers MH (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100:2257-2259 (Pubitemid 35001266)
85. Veit O, Niedrig M, Chapius-Taillard C, Cavassini M, Mossdorf E, Schmid P, Bae HG, Litzba N, Staub T, Hatz C, Furrer H, Swiss HIV Cohort Study (2009) Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48:659-666
86. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B (2008) Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 46:1078-1084 (Pubitemid 351589876)